Unknown

Dataset Information

0

A Bitter Taste Receptor as a Novel Molecular Target on Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma.


ABSTRACT: Cancer-associated fibroblasts (CAFs) execute diverse and complex functions in cancer progression. While reprogramming the crosstalk between CAFs and cancer epithelial cells is a promising avenue to evade the adverse effects of stromal depletion, drugs are limited by their suboptimal pharmacokinetics and off-target effects. Thus, there is a need to elucidate CAF-selective cell surface markers that can improve drug delivery and efficacy. Here, functional proteomic pulldown with mass spectrometry was used to identify taste receptor type 2 member 9 (TAS2R9) as a CAF target. TAS2R9 target characterization included binding assays, immunofluorescence, flow cytometry, and database mining. Liposomes conjugated to a TAS2R9-specific peptide were generated, characterized, and compared to naked liposomes in a murine pancreatic xenograft model. Proof-of-concept drug delivery experiments demonstrate that TAS2R9-targeted liposomes bind with high specificity to TAS2R9 recombinant protein and exhibit stromal colocalization in a pancreatic cancer xenograft model. Furthermore, the delivery of a CXCR2 inhibitor by TAS2R9-targeted liposomes significantly reduced cancer cell proliferation and constrained tumor growth through the inhibition of the CXCL-CXCR2 axis. Taken together, TAS2R9 is a novel cell-surface CAF-selective target that can be leveraged to facilitate small-molecule drug delivery to CAFs, paving the way for new stromal therapies.

SUBMITTER: Hung J 

PROVIDER: S-EPMC10058050 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Bitter Taste Receptor as a Novel Molecular Target on Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma.

Hung Jessica J   Perez Samantha M SM   Dasa Siva Sai Krishna SSK   Hall Sarah P SP   Heckert Danielle B DB   Murphy Brian P BP   Crawford Howard C HC   Kelly Kimberly A KA   Brinton Lindsey T LT  

Pharmaceuticals (Basel, Switzerland) 20230303 3


Cancer-associated fibroblasts (CAFs) execute diverse and complex functions in cancer progression. While reprogramming the crosstalk between CAFs and cancer epithelial cells is a promising avenue to evade the adverse effects of stromal depletion, drugs are limited by their suboptimal pharmacokinetics and off-target effects. Thus, there is a need to elucidate CAF-selective cell surface markers that can improve drug delivery and efficacy. Here, functional proteomic pulldown with mass spectrometry w  ...[more]

Similar Datasets

| S-EPMC6422180 | biostudies-literature
| S-EPMC10299363 | biostudies-literature
| S-EPMC9596464 | biostudies-literature
| S-EPMC6560132 | biostudies-literature
| S-EPMC8106654 | biostudies-literature
| S-EPMC7926036 | biostudies-literature
| S-EPMC10410818 | biostudies-literature
| S-EPMC4513646 | biostudies-literature
| S-EPMC3750050 | biostudies-literature
| S-EPMC7501205 | biostudies-literature